Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 569 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Art Therapy Clear all
Completed No phase listed Observational

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

NCT00000890
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 15, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

NCT06075264
View directory record Official record
Conditions
Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions
Artesunate ointment, Placebo ointment
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

NCT00987948
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc (Selzentry)
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

NCT01969409
View directory record Official record
Conditions
Ambulatory IPF
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

NCT00002199
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
16 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

NCT00114699
View directory record Official record
Conditions
HIV Infections
Interventions
CCR5mAb004
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Fort Lauderdale, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 15, 2026, 2:03 AM EDT
Recruiting Not applicable Interventional

reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)

NCT05958017
View directory record Official record
Conditions
Stimulant Use Disorder, People Living With HIV
Interventions
reSET, Standard of care
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

NCT00001091
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Months to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 15, 2026, 2:03 AM EDT
Active, not recruiting Phase 4 Interventional

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir, Emtricitabine/Tenofovir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Results available

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

NCT05604209
View directory record Official record
Conditions
HIV Vaccine, HIV-1-infection
Interventions
ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4, MVA.tHIVconsv3, Placebo
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

NCT01839734
View directory record Official record
Conditions
HIV
Interventions
Lubiprostone
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

NCT00002332
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Tarzana, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 2:03 AM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children

NCT00002219
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
St. Petersburg, Florida • New Orleans, Louisiana • Great Neck, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 2:03 AM EDT
Completed No phase listed Observational Results available

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers

NCT01723163
View directory record Official record
Conditions
Veteran, Smoking Cessation
Interventions
Abstinence Reinforcement Therapy (ART), Telephone Counseling and NRT
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Not applicable Interventional

eMove - Dance/Movement Therapy Study

NCT05712928
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Dance/movement therapy (eMove)
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 15, 2026, 2:03 AM EDT
Completed No phase listed Observational

Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy

NCT00001899
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 15, 2026, 2:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Compartmental Biology of HIV in the Male Genital Tract

NCT02638493
View directory record Official record
Conditions
Human Immunodeficiency Virus, Virus Shedding
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 15, 2026, 2:03 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581
View directory record Official record
Conditions
HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
Interventions
SV2A PET, TSPO PET
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Vitamin D in HIV-Infected Patients on HAART

NCT01250899
View directory record Official record
Conditions
Vitamin D Deficiency, HIV
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

NCT00011011
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 15, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

NCT00367458
View directory record Official record
Conditions
HIV
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 15, 2026, 2:03 AM EDT